Table 3. Subgroup analysis.

	Subgroup analysis	No. of trials (reference nos.)	No. of patients	I2	RR [95% CI]	P value
Clinical efficacy rates	Overall	7 (15–18,24,25,27)	492	0	1.29 [1.17, 1.42]	<0.0001
	Type of intervention
	Including TCM	5 (15–17,24,25)	362	0	1.22 [1.11, 1.35]	<0.0001
	Without TCM	2 (18,27)	130	0	1.56 [1.17, 2.07]	0.002
	Intervention course
	20–50 days	5 (15,18,24,25,27)	331	0	1.33 [1.17, 1.52]	<0.0001
	51–90 days	2 (16,17)	161	21	1.21 [1.06, 1.39]	0.006
	AMD type
	Dry AMD	2 (24,25)	132	0	1.22 [1.05, 1.42]	0.01
	Wet AMD	3 (15,16,18)	196	18	1.26 [1.06, 1.50]	0.01
	Dry and wet AMD	2(17,27)	164	0	1.39 [1.16, 1.65]	0.0002
	Subgroup analysis	No. of trials (reference nos.)	No. of patients	I 2	SMD [95% CI]	P value
BCVA	Overall	5 (16–18,23,25)	335	89%	0.95 [0.26,1.64]	0.007
	Type of intervention
	Including TCM	3 (16,17,25)	221	56%	0.76 [0.34, 1.18]	0.0004
	Without TCM	2 (18,23)	114	96%	1.23 [-1.00, 3.46]	0.28
	Intervention course
	20–50 days	2 (18,25)	100	65%	0.47 [-0.22, 1.16]	0.18
	50–90 days	3 (16,17,23)	235	93%	1.28 [0.21, 2.34]	0.02
	AMD type
	Dry AMD	2 (23,25)	134	93	1.58 [0.04, 3.11]	0.04
	Wet AMD	2 (16,18)	127	0	0.31 [-0.04, 0.66]	0.09
	Dry and wet AMD	1 (17)	74	NA	1.11 [0.62, 1.60]	<0.0001
	Subgroup analysis	No. of trials (reference nos.)	No. of patients	I 2	MD [95% CI]	P value
CMT	Overall	3(16–18)	201	67%	-32.74 [-60.94, -4.55]	0.02
	Type of intervention
	Including TCM	2 (16,17)	161	83%	-31.69 [-71.37, 7.99]	0.12
	Without TCM	1 (18)	40	NA	-32.60 [-77.59, 12.39]	0.16
	Intervention course
	20–50 days	1 (18)	40	NA	-32.60 [-77.59, 12.39]	0.16
	51–90 days	2 (16,17)	161	83%	-31.69 [-71.37, 7.99]	0.12
	AMD type
	Wet AMD	2 (16,18)	127	0	-16.21 [-40.80, 8.39]	0.2
	Dry and wet AMD	1 (17)	74	NA	-49.93 [-64.13, -35.73]	<0.0001

NA, not applicable.